Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context
- 1 November 2020
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 140, 76-85
Abstract
No abstract availableKeywords
Funding Information
- Universität Duisburg-Essen
- Deutsche Forschungsgemeinschaft
- Bristol-Myers Squibb
This publication has 30 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expressionGenome Biology, 2016
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaNew England Journal of Medicine, 2016
- Monitoring immune responses in the tumor microenvironmentCurrent Opinion in Immunology, 2016
- The “cancer immunogram”Science, 2016
- Loss of PTEN Promotes Resistance to T Cell–Mediated ImmunotherapyCancer Discovery, 2016
- Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers2016
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- The future of immune checkpoint therapyScience, 2015
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic ActivityCell, 2015